IC
CPRX

Ikarian Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Ikarian Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,388
Closed -$1.34M – 179
2025
Q4 		$1.34M Sell
57,388
-59,000
-51% -$1.31M 0.1% 122
2025
Q3 		$2.29M Sell
116,388
-93,261
-44% -$1.92M 0.23% 93
2025
Q2 		$4.55M Sell
209,649
-40,000
-16% -$944K 0.87% 34
2025
Q1 		$6.05M Sell
249,649
-100,000
-29% -$2.25M 0.75% 29
2024
Q4 		$7.3M Sell
349,649
-68,201
-16% -$1.47M 0.99% 26
2024
Q3 		$8.31M Sell
417,850
-100,536
-19% -$1.86M 1.16% 23
2024
Q2 		$8.03M Hold
518,386
– – 1.4% 23
2024
Q1 		$8.26M Buy
518,386
+12,524
+2% +$189K 0.91% 34
2023
Q4 		$8.5M Hold
505,862
– – 0.8% 44
2023
Q3 		$5.91M Buy
+505,862
New +$6.77M 0.71% 42

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ikarian Capital's CPRX Position: Q1 2026 in Review

Ikarian Capital sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 57,388 shares — an estimated $1.34M sold.

Ikarian Capital first reported a position in CPRX in Q3 2023 and held it in 10 quarters. The position peaked at $8.5M in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ikarian Capital reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 57,388 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.34M.
  • Ikarian Capital first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 10 quarters.
  • Ikarian Capital's Catalyst Pharmaceutical position peaked at $8.5M in Q4 2023.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.